{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:28:47Z","timestamp":1793777327832,"version":"4.6.1"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR210085"],"award-info":[{"award-number":["RR210085"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016618","name":"Gilbert Family Foundation","doi-asserted-by":"publisher","award":["622030"],"award-info":[{"award-number":["622030"]}],"id":[{"id":"10.13039\/100016618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lindonlight Collective"},{"name":"Penny\u2019s Flight Foundation"},{"DOI":"10.13039\/100001794","name":"Pediatric Brain Tumor Foundation","doi-asserted-by":"publisher","award":["P30-EY008098"],"award-info":[{"award-number":["P30-EY008098"]}],"id":[{"id":"10.13039\/100001794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vision impairment is a significant concern for children with neurofibromatosis type 1 (NF1)-associated optic pathway glioma (OPG). While carboplatin-containing chemotherapy is often first-line therapy for NF1-OPG, it does not consistently improve visual function. Furthermore, chemotherapy is associated with altered white matter microstructure in individuals with NF1-OPG, suggesting a detrimental effect on oligodendroglia. We analyzed the tumor-independent effects of carboplatin on oligodendrocytes in Nf1-mutant mice and evaluated pharmacological strategies for reducing this chemotherapy-associated toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Carboplatin- or vehicle-treated Nf1+\/\u2212 mice or Nf1-mutant optic glioma cells were employed to assess the effects of restorative interventions on optic nerve oligodendrocytes in vivo and tumor cell growth in vitro, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Clinically relevant carboplatin dosing induced oligodendrocyte loss and impaired myelin sheath structure in the optic nerves of Nf1+\/\u2212 mice, an effect not observed following vinca alkaloids or MEK inhibitor (selumetinib) treatment. Carboplatin downregulates genes essential for cholesterol biosynthesis and decreases cholesterol levels in Nf1+\/\u2212 optic nerves, such that dietary cholesterol supplementation after carboplatin exposure restored oligodendrocyte numbers. Carboplatin also increases the density of monocytes (microglia\/macrophages) in the Nf1+\/\u2212 optic nerves. Using PLX5622 (a CSF1R inhibitor) to reduce monocyte numbers or using clemastine to promote the generation and survival of oligodendrocytes, alleviated the oligodendrocyte loss caused by carboplatin treatment. Notably, PLX5622 and clemastine reduced the viability of Nf1-mutant optic glioma tumor cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings demonstrate that carboplatin induces oligodendroglial toxicity in Nf1-mutant optic nerves, which can be mitigated by clemastine, PLX5622, or dietary cholesterol following carboplatin exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag163","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:34:18Z","timestamp":1784633658000},"page":"2609-2620","source":"Crossref","is-referenced-by-count":0,"title":["Carboplatin induces optic nerve oligodendrocyte loss and impairs myelin sheath microstructure in a mouse model of neurofibromatosis type 1"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5630-1361","authenticated-orcid":false,"given":"Benjamin E","family":"Aghoghovwia","sequence":"first","affiliation":[{"name":"Department of Translational Neuroscience, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kechen","family":"Ban","sequence":"additional","affiliation":[{"name":"Department of Translational Neuroscience, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Stavropoulos","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, UPMC Vision Institute, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1245-0888","authenticated-orcid":false,"given":"Chi-Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, UPMC Vision Institute, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5573-5715","authenticated-orcid":false,"given":"Bo","family":"Wei","sequence":"additional","affiliation":[{"name":"Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava S","family":"Hamblett","sequence":"additional","affiliation":[{"name":"Department of Translational Neuroscience, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2437-9501","authenticated-orcid":false,"given":"Samer","family":"Sharafaldin","sequence":"additional","affiliation":[{"name":"Department of Translational Neuroscience, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8084-4922","authenticated-orcid":false,"given":"Hana","family":"El-Toukhy","sequence":"additional","affiliation":[{"name":"Department of Translational Neuroscience, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4606-8590","authenticated-orcid":false,"given":"Momo","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Translational Neuroscience, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0207-2978","authenticated-orcid":false,"given":"Chhay","family":"Hok","sequence":"additional","affiliation":[{"name":"Department of Translational Neuroscience, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3087-6330","authenticated-orcid":false,"given":"Varsha K","family":"Chandramouli","sequence":"additional","affiliation":[{"name":"Department of Translational Neuroscience, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1265-1030","authenticated-orcid":false,"given":"Carlos Manuel","family":"Mart\u00ednez Cerda","sequence":"additional","affiliation":[{"name":"Department of Translational Neuroscience, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]},{"name":"Facultad de Medicina, Universidad de Monterrey, San Pedro Garza Garc\u00eda , Nuevo Le\u00f3n,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8442-203X","authenticated-orcid":false,"given":"Renae E","family":"Bertrand","sequence":"additional","affiliation":[{"name":"Department of Translational Neuroscience, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0129-8883","authenticated-orcid":false,"given":"Sama","family":"Alnassiry","sequence":"additional","affiliation":[{"name":"Department of Translational Neuroscience, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-7774","authenticated-orcid":false,"given":"Philip L","family":"Lorenzi","sequence":"additional","affiliation":[{"name":"Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]},{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center , Duarte, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-5045","authenticated-orcid":false,"given":"David H","family":"Gutmann","sequence":"additional","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine , St. Louis, Missouri,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0871-5612","authenticated-orcid":false,"given":"Kun-Che","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, UPMC Vision Institute, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2228-5628","authenticated-orcid":false,"given":"Rajasekaran","family":"Mahalingam","sequence":"additional","affiliation":[{"name":"Department of Translational Neuroscience, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9465-8289","authenticated-orcid":false,"given":"Yuan","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Translational Neuroscience, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]},{"name":"Cancer Neuroscience Program, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]},{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"2026110401530945800_noag163-B1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/pbc.22198","article-title":"Natural history and outcome of optic pathway gliomas in children","volume":"53","author":"Nicolin","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"2026110401530945800_noag163-B2","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1200\/JCO.1993.11.5.850","article-title":"Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood","volume":"11","author":"Packer","year":"1993","journal-title":"J Clin Oncol"},{"key":"2026110401530945800_noag163-B3","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/ICU.0000000000000587","article-title":"Current treatment of optic nerve gliomas","volume":"30","author":"Farazdaghi","year":"2019","journal-title":"Curr Opin Ophthalmol"},{"key":"2026110401530945800_noag163-B4","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026110401530945800_noag163-B5","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1093\/neuonc\/noaf065","article-title":"A phase 2 PBTC study of selumetinib for recurrent\/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4","volume":"27","author":"Fangusaro","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026110401530945800_noag163-B6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/neuonc\/nos076","article-title":"Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis","volume":"14","author":"Fisher","year":"2012","journal-title":"Neuro Oncol"},{"key":"2026110401530945800_noag163-B7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/jbiol50","article-title":"CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo","volume":"5","author":"Dietrich","year":"2006","journal-title":"J Biol"},{"key":"2026110401530945800_noag163-B8","doi-asserted-by":"publisher","first-page":"35581","DOI":"10.18632\/oncotarget.26272","article-title":"Nasal administration of mesenchymal stem cells restores cisplatin-induced cognitive impairment and brain damage in mice","volume":"9","author":"Chiu","year":"2018","journal-title":"Oncotarget"},{"key":"2026110401530945800_noag163-B9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cell.2018.10.049","article-title":"Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment","volume":"176","author":"Gibson","year":"2019","journal-title":"Cell"},{"key":"2026110401530945800_noag163-B10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neuroscience.2022.01.001","article-title":"Clemastine rescues chemotherapy-induced cognitive impairment by improving white matter integrity","volume":"484","author":"Chen","year":"2022","journal-title":"Neuroscience"},{"key":"2026110401530945800_noag163-B11","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/pbc.25896","article-title":"Systemic chemotherapy and white matter integrity in tracts associated with cognition among children with neurofibromatosis type 1: chemotherapy and white matter integrity in NF1","volume":"63","author":"De Blank","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"2026110401530945800_noag163-B12","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/s41593-024-01654-y","article-title":"Nf1 mutation disrupts activity-dependent oligodendroglial plasticity and motor learning in mice","volume":"27","author":"Pan","year":"2024","journal-title":"Nat Neurosci"},{"key":"2026110401530945800_noag163-B13","doi-asserted-by":"publisher","first-page":"52474","DOI":"10.18632\/oncotarget.17193","article-title":"Whole tumor RNA-sequencing and deconvolution reveal a clinically-prognostic PTEN\/PI3K-regulated glioma transcriptional signature","volume":"8","author":"Pan","year":"2017","journal-title":"Oncotarget"},{"key":"2026110401530945800_noag163-B14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41531-024-00640-2","article-title":"Microglial inhibition alleviates alpha-synuclein propagation and neurodegeneration in parkinson\u2019s disease mouse model","volume":"10","author":"Thi Lai","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"2026110401530945800_noag163-B15","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1038\/s41598-024-53615-x","article-title":"Clemastine and metformin extend the window of NMDA receptor surface expression in ageing oligodendrocyte precursor cells","volume":"14","author":"Kamen","year":"2024","journal-title":"Sci Rep"},{"key":"2026110401530945800_noag163-B16","doi-asserted-by":"publisher","first-page":"14241","DOI":"10.1038\/ncomms14241","article-title":"Dietary cholesterol promotes repair of demyelinated lesions in the adult brain","volume":"8","author":"Berghoff","year":"2017","journal-title":"Nat Commun"},{"key":"2026110401530945800_noag163-B17","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1\u2013related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"},{"key":"2026110401530945800_noag163-B18","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"key":"2026110401530945800_noag163-B19","doi-asserted-by":"publisher","first-page":"110423","DOI":"10.1016\/j.celrep.2022.110423","article-title":"Cholesterol biosynthesis defines oligodendrocyte precursor heterogeneity between brain and spinal cord","volume":"38","author":"Khandker","year":"2022","journal-title":"Cell Rep"},{"key":"2026110401530945800_noag163-B20","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.chembiol.2019.01.004","article-title":"Diverse chemical scaffolds enhance oligodendrocyte formation by inhibiting CYP51, TM7SF2, or EBP","volume":"26","author":"Allimuthu","year":"2019","journal-title":"Cell Chem Biol"},{"key":"2026110401530945800_noag163-B21","doi-asserted-by":"publisher","first-page":"149932","DOI":"10.1016\/j.bbrc.2024.149932","article-title":"DHCR7 links cholesterol synthesis with neuronal development and axonal integrity","volume":"712-713","author":"Miyazaki","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"2026110401530945800_noag163-B22","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/nm.3618","article-title":"Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis","volume":"20","author":"Mei","year":"2014","journal-title":"Nat Med"},{"key":"2026110401530945800_noag163-B23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/oxfordjournals.annonc.a058497","article-title":"Ophthalmic toxicity during carboplatin therapy","volume":"4","author":"Rankin","year":"1993","journal-title":"Ann Oncol"},{"key":"2026110401530945800_noag163-B24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF00167362","article-title":"Retinal changes induced by treatment with vincristine and vinblastine","volume":"31","author":"Hansson","year":"1972","journal-title":"Doc Ophthalmol"},{"key":"2026110401530945800_noag163-B25","doi-asserted-by":"publisher","first-page":"e31709","DOI":"10.1002\/pbc.31709","article-title":"Ocular safety and visual acuity stability in pediatric patients with optic pathway gliomas and orbital plexiform neurofibromas treated with BRAF and MEK inhibitors","volume":"72","author":"Sever","year":"2025","journal-title":"Pediatric Blood Cancer"},{"key":"2026110401530945800_noag163-B26","doi-asserted-by":"publisher","first-page":"a020479","DOI":"10.1101\/cshperspect.a020479","article-title":"Oligodendrocytes: myelination and axonal support","volume":"8","author":"Simons","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2026110401530945800_noag163-B27","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1093\/neuonc\/noaf024","article-title":"Intestinal bacteroides drives glioma progression by regulating CD8+ T cell tumor infiltration","volume":"27","author":"Chatterjee","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026110401530945800_noag163-B28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2261-13-18","article-title":"Non-invasive endothelial function assessment in patients with neurofibromatosis type 1: a cross-sectional study","volume":"13","author":"Rodrigues","year":"2013","journal-title":"BMC Cardiovasc Disord"},{"key":"2026110401530945800_noag163-B29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/path.2370","article-title":"Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas","volume":"216","author":"Komohara","year":"2008","journal-title":"J Pathol"},{"key":"2026110401530945800_noag163-B30","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1158\/0008-5472.CAN-09-4674","article-title":"Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas","volume":"70","author":"Bender","year":"2010","journal-title":"Cancer Res"},{"key":"2026110401530945800_noag163-B31","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med"},{"key":"2026110401530945800_noag163-B32","doi-asserted-by":"publisher","first-page":"aad3018","DOI":"10.1126\/science.aad3018","article-title":"The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas","volume":"352","author":"Quail","year":"2016","journal-title":"Science (1979)"},{"key":"2026110401530945800_noag163-B33","first-page":"8573","article-title":"Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity","volume":"63","author":"Bajenaru","year":"2003","journal-title":"Cancer Res"},{"key":"2026110401530945800_noag163-B34","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.neo.2015.10.002","article-title":"RNA sequencing of tumor-associated microglia reveals Ccl5 as a stromal chemokine critical for neurofibromatosis-1 glioma growth","volume":"17","author":"Solga","year":"2015","journal-title":"Neoplasia"},{"key":"2026110401530945800_noag163-B35","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1093\/neuonc\/noz080","article-title":"Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia","volume":"21","author":"Guo","year":"2019","journal-title":"Neuro Oncol"},{"key":"2026110401530945800_noag163-B36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/ana.23813","article-title":"Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation","volume":"73","author":"Pong","year":"2013","journal-title":"Ann Neurol"},{"key":"2026110401530945800_noag163-B37","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/hmg\/ddm059","article-title":"Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth","volume":"16","author":"Daginakatte","year":"2007","journal-title":"Hum Mol Genet"},{"key":"2026110401530945800_noag163-B38","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.it.2020.07.001","article-title":"To kill a microglia: a case for CSF1R inhibitors","volume":"41","author":"Green","year":"2020","journal-title":"Trends Immunol"},{"key":"2026110401530945800_noag163-B39","doi-asserted-by":"publisher","first-page":"1582902","DOI":"10.3389\/fncel.2025.1582902","article-title":"The potential of repurposing clemastine to promote remyelination","volume":"19","author":"Yamazaki","year":"2025","journal-title":"Front Cell Neurosci"},{"key":"2026110401530945800_noag163-B40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/brain\/awx312","article-title":"Clemastine rescues myelination defects and promotes functional recovery in hypoxic brain injury","volume":"141","author":"Cree","year":"2018","journal-title":"Brain"},{"key":"2026110401530945800_noag163-B41","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1038\/s41467-020-17871-5","article-title":"Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas-Casp8-Bid-axis","volume":"11","author":"Carlstr\u00f6m","year":"2020","journal-title":"Nat Commun"},{"key":"2026110401530945800_noag163-B42","doi-asserted-by":"publisher","first-page":"115435","DOI":"10.1016\/j.bcp.2023.115435","article-title":"Modulation of p38 MAPK and Nrf2\/HO-1\/NLRP3 inflammasome signaling and pyroptosis outline the anti-neuroinflammatory and remyelinating characters of clemastine in EAE rat model","volume":"209","author":"Motawi","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"2026110401530945800_noag163-B43","doi-asserted-by":"publisher","first-page":"111481","DOI":"10.1016\/j.intimp.2023.111481","article-title":"The preferential effect of clemastine on F3\/contactin-1\/notch-1 compared to jagged-1\/notch-1 justifies its remyelinating effect in an experimental model of multiple sclerosis in rats","volume":"128","author":"Ibrahim","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2026110401530945800_noag163-B44","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial","volume":"390","author":"Green","year":"2017","journal-title":"Lancet"},{"key":"2026110401530945800_noag163-B45","doi-asserted-by":"publisher","first-page":"e183941","DOI":"10.1172\/JCI183941","article-title":"Clemastine fumarate accelerates accumulation of disability in progressive multiple sclerosis by enhancing pyroptosis","volume":"135","author":"Kocot","year":"2025","journal-title":"J Clin Invest"},{"key":"2026110401530945800_noag163-B46","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.ccell.2025.07.024","article-title":"Long-range cholinergic input promotes glioblastoma progression","volume":"43","author":"Yang","year":"2025","journal-title":"Cancer Cell. Published"},{"key":"2026110401530945800_noag163-B47","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1016\/j.cell.2025.05.031","article-title":"Cholinergic neuronal activity promotes diffuse midline glioma growth through muscarinic signaling","volume":"188","author":"Drexler","year":"2025","journal-title":"Cell"},{"key":"2026110401530945800_noag163-B48","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41586-025-08634-7","article-title":"Brain-wide neuronal circuit connectome of human glioblastoma","volume":"641","author":"Sun","year":"2025","journal-title":"Nature"},{"key":"2026110401530945800_noag163-B49","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2147\/CMAR.S362678","article-title":"Neurofibromatosis type 1-associated optic pathway gliomas: current challenges and future prospects","volume":"15","author":"Tang","year":"2023","journal-title":"Cancer Manag Res"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag163\/69749401\/noag163.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/11\/2609\/69749401\/noag163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/11\/2609\/69749401\/noag163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:53:12Z","timestamp":1793775192000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/11\/2609\/8739532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":49,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,7,21]]},"published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag163","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,7,21]]}}}